M D I Vergouwen1, P A C A Beentjes, P J Nederkoorn. 1. Department of Neurology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. m.d.vergouwen@amc.uva.n
Abstract
BACKGROUND AND PURPOSE: No data of randomized controlled trials investigating the effect of thrombolysis in patients with ischemic stroke caused by an extracranial dissection are available. Previous case series suggested that thrombolysis in this group of patients is safe and improves outcome, however publication bias may play a role. The purpose of the present study was to describe outcome of consecutive patients with ischemic stroke caused by an extracranial dissection treated with recombinant tissue plasminogen activator (rtPA), derived from a well-defined ischemic stroke cohort. METHODS: All consecutive patients with a transient ischemic attack (TIA) or ischemic stroke admitted to the Academic Medical Center Amsterdam between January 1, 2007 and September 1, 2007 were prospectively registered. Cause of TIA/stroke, treatment, and 6-months outcome were recorded. RESULTS: During the study period 252 patients were evaluated with TIA or ischemic stroke. Eight patients (3%) had an extracranial dissection. Of the six rtPA treated patients, five had good clinical outcome and one patient died. The two patients who were not treated with rtPA, because of minor stroke, had good clinical outcome 6 months after index event. DISCUSSION: Treatment with rtPA seems to be safe and feasible in ischemic stroke patients with an extracranial dissection.
BACKGROUND AND PURPOSE: No data of randomized controlled trials investigating the effect of thrombolysis in patients with ischemic stroke caused by an extracranial dissection are available. Previous case series suggested that thrombolysis in this group of patients is safe and improves outcome, however publication bias may play a role. The purpose of the present study was to describe outcome of consecutive patients with ischemic stroke caused by an extracranial dissection treated with recombinant tissue plasminogen activator (rtPA), derived from a well-defined ischemic stroke cohort. METHODS: All consecutive patients with a transient ischemic attack (TIA) or ischemic stroke admitted to the Academic Medical Center Amsterdam between January 1, 2007 and September 1, 2007 were prospectively registered. Cause of TIA/stroke, treatment, and 6-months outcome were recorded. RESULTS: During the study period 252 patients were evaluated with TIA or ischemic stroke. Eight patients (3%) had an extracranial dissection. Of the six rtPA treated patients, five had good clinical outcome and one patient died. The two patients who were not treated with rtPA, because of minor stroke, had good clinical outcome 6 months after index event. DISCUSSION: Treatment with rtPA seems to be safe and feasible in ischemic strokepatients with an extracranial dissection.
Authors: Georgios Tsivgoulis; Ramin Zand; Aristeidis H Katsanos; Vijay K Sharma; Nitin Goyal; Christos Krogias; Apostolos Safouris; Konstantinos Vadikolias; Konstantinos Voumvourakis; Anne W Alexandrov; Marc D Malkoff; Andrei V Alexandrov Journal: J Neurol Date: 2015-06-25 Impact factor: 4.849
Authors: Christopher Traenka; Simon Jung; Jan Gralla; Rebekka Kurmann; Christoph Stippich; Barbara Goeggel Simonetti; Henrik Gensicke; Hubertus Mueller; Karl Lovblad; Ashraf Eskandari; Francesco Puccinelli; Jochen Vehoff; Johannes Weber; Susanne Wegener; Levke Steiner; Georg Kägi; Andreas Luft; Roman Sztajzel; Urs Fischer; Leo H Bonati; Nils Peters; Patrik Michel; Philippe A Lyrer; Marcel Arnold; Stefan T Engelter Journal: Eur Stroke J Date: 2018-01-03